Delivering a disease-modifying treatment for Huntington's disease

Drug Discovery Today

Volumn 20, Issue 1, 2015, Pages 50-64

  Godinho, Bruno M D C ^a   Malhotra, Meenakshi ^a   O'Driscoll, Caitriona M ^a   Cryan, John F ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DEOXYRIBOZYME; NUCLEIC ACID; RIBOZYME; RNA; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ALLELE; DRUG MECHANISM; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; NONHUMAN; REVIEW; RNA INTERFERENCE; ANIMAL; GENETICS; HUMAN GENOME; HUNTINGTON DISEASE; METABOLISM;

ALLELES; ANIMALS; GENE SILENCING; GENOME, HUMAN; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS;

EID: 84922460332     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.09.011     Document Type: Review

References (143)

1. Morrison, P.J. (2010) Accurate prevalence and uptake of testing for Huntington's disease. Lancet Neurol. 9, 1147
2. Pringsheim, T. et al. (2012) The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov. Disord. 27, 1083-1091
3. Wexler, N.S. (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. U. S. A. 101, 3498
4. Bates, G. et al. (2002) Huntington's Disease. Oxford University Press
5. Ross, C.A. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98
6. MacDonald, M.E. et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983
7. Imarisio, S. et al. (2008) Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 412, 191-209
8. Hockly, E. et al. (2002) Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 51, 235-242
9. Spires, T.L. et al. (2004) Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J. Neurosci. 24, 2270-2276
10. Sah, D.W. and Aronin, N. (2011) Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest. 121, 500-507
11. Scanlon, K.J. (2004) Anti-genes: siRNA, ribozymes and antisense. Curr. Pharm. Biotechnol. 5, 415-420
12. Tanner, N.K. (1999) Ribozymes: the characteristics and properties of catalytic RNAs. FEMS Microbiol. Rev. 23, 257-275
13. Birikh, K.R. et al. (1997) The structure, function and application of the hammerhead ribozyme. Eur. J. Biochem. 245, 1-16
14. Cech, T.R. (2009) Crawling out of the RNA world. Cell 136, 599-602
15. Denovan-Wright, E.M. et al. (2008) Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiol. Dis. 29, 446-455
16. Rodriguez-Lebron, E. et al. (2005) Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12, 618-633
17. Hayashita-Kinoh, H. et al. (2006) Down-regulation of a-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem. Biophys. Res. Commun. 341, 1088-1095
18. Ben Aissa, M. et al. (2012) Silencing of amyloid precursor protein expression using a new engineered delta ribozyme. Int. J. Alzheimer's Dis. 2012 http://dx.doi.org/10.1155/2012/947147 Article ID: 947147
19. Phylactou, L.A. et al. (1998) Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nat. Genet. 18, 378-381
20. Schlosser, K. and Li, Y. (2009) Biologically inspired synthetic enzymes made from DNA. Chem. Biol. 16, 311-322
21. Yen, L. et al. (1999) Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA. Ann. Neurol. 46, 366-373
22. Southwell, A.L. et al. (2012) Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends Mol. Med. 18, 634-643
23. Chan, J.H. et al. (2006) Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol. 33, 533-540
24. Smith, R.A. et al. (2006) Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 2290-2296
25. Bertrand, J.R. et al. (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296, 1000-1004
26. Haque, N. and Isacson, O. (1997) Antisense gene therapy for neurodegenerative disease? Exp. Neurol. 144, 139-146
27. Gagnon, K.T. et al. (2010) Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49, 10166-10178
28. Hu, J. et al. (2009) Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann. N. Y. Acad. Sci. 1175, 24-31
29. Carroll, J.B. et al. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178-2185
30. Kordasiewicz, H.B. et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044
31. Ostergaard, M.E. et al. (2013) Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 41, 9634-9650
32. Miller, T.M. et al. (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435-442
33. Miyagishi, M. et al. (2003) Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug. Dev. 13, 1-7
34. Napoli, C. et al. (1990) Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell Online 2, 279-289
35. Fire, A. et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811
36. Elbashir, S.M. et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498
37. Stefani, G. and Slack, F.J. (2008) Small non-coding RNAs in animal development. Nat. Rev. Mol. Cell Biol. 9, 219-230
38. He, L. and Hannon, G.J. (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531
39. Agrawal, N. et al. (2003) RNA interference: biology, mechanism, and applications. Microbiol. Mol. Biol. Rev. 67, 657-685
40. Zamore, P.D. et al. (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25-33
41. Martinez, J. et al. (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-574
42. Singh, S. et al. (2011) Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm. Res. 28, 2996-3015
43. Pardridge, W.M. (2007) shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev. 59, 141-152
44. Thakker, D.R. et al. (2006) Interfering with the brain: use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol. Ther. 109, 413-438
45. Thakker, D.R. et al. (2005) siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol. Psychiatry 10, 782-789 714
46. Zhang, P. (2008) Transgenic RNA interference in mice. Methods Mol. Biol. 442, 259-266
47. Gao, X. and Zhang, P. (2007) Transgenic RNA interference in mice. Physiology 22, 161-166
48. Hitz, C. et al. (2009) Generation of shRNA transgenic mice. Gene Knockout Protoc. 530, 101-129
49. Aagaard, L. and Rossi, J.J. (2007) RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59, 75-86
50. Kim, D.H. and Rossi, J.J. (2007) Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8, 173-184
51. Fougerolles, A.D. et al. (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6, 443-453
52. Caplen, N.J. et al. (2002) Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum. Mol. Genet. 11, 175-184
53. Chen, Z.J. et al. (2005) Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. Biochem. Biophys. Res. Commun. 329, 646-652
54. Harper, S.Q. et al. (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 102, 5820-5825
55. Wang, Y.L. et al. (2005) Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. Res. 53, 241-249
56. Godinho, B.M. et al. (2013) Self-assembling modified beta-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease. Mol. Pharm. 10, 640-649
57. DiFiglia, M. et al. (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 104, 17204-17209
58. Machida, Y. et al. (2006) rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Commun. 343, 190-197
59. Drouet, V. et al. (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 65, 276-285
60. O'Mahony, A.M. et al. (2013) Non-viral nanosystems for gene and siRNA delivery to the central nervous system: formulating the solution. J. Pharm. Sci. 102, 3469-3484
61. Lentz, T.B. et al. (2012) Viral vectors for gene delivery to the central nervous system. Neurobiol. Dis. 48, 179-188
62. Thomas, C.E. et al. (2003) Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4, 346-358
63. Hasholt, L. et al. (2003) Antisense downregulation of mutant huntingtin in a cell model. J. Gene Med. 5, 528-538
64. Evers, M.M. et al. (2011) Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS ONE 6, e24308
65. Godinho, B.M.D.C. et al. (2014) Differential nanotoxicological and neuroinflammatory liabilities of non-viral vectors for RNA interference in the central nervous system. Biomaterials 35, 489-499
66. Akhtar, S. and Benter, I. (2007) Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv. Drug Deliv. Rev. 59, 164-182
67. Dobrovolskaia, M.A. and McNeil, S.E. (2007) Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2, 469-478
68. Bonnet, M-E. et al. (2008) Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm. Res. 25, 2972-2982
69. Rigamonti, D. et al. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 20, 3705-3713
70. Malhotra, M. et al. (2011) Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. Expert Opin. Drug Discov. 6, 269-289
71. Jackson, A.L. and Linsley, P.S. (2010) Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9, 57-67
72. Sledz, C.A. et al. (2003) Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834-839
73. Sioud, M. (2005) Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J. Mol. Biol. 348, 1079-1090
74. Hornung, V. et al. (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270
75. Karikó, K. et al. (2004) Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J. Immunol. 172, 6545-6549
76. Persengiev, S.P. et al. (2004) Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10, 12-18
77. Naito, Y. et al. (2004) siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference. Nucleic Acids Res. 32 (Suppl. 2), W124-W129
78. Reynolds, A. et al. (2004) Rational siRNA design for RNA interference. Nat. Biotechnol. 22, 326-330
79. Eberle, F. et al. (2008) Modifications in small interfering RNA that separate immunostimulation from RNA interference. J. Immunol. 180, 3229-3237
80. Layser, J.M. et al. (2004) In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-771
81. Grimm, D. et al. (2006) Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541
82. Borel, F. et al. (2011) In vivo knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. J. RNAi Gene Silencing 7, 434-442
83. Barik, S. (2006) RNAi in moderation. Nat. Biotechnol. 24, 796-797
84. Martin, J.N. et al. (2011) Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther. 18, 666-673
85. Yi, R.U.I. et al. (2005) Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA 11, 220-226
86. Boudreau, R.L. et al. (2009) Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol. Ther. 17, 169-175
87. McBride, J.L. et al. (2008) Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U. S. A. 105, 5868-5873
88. Squitieri, F. et al. (2003) Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 126, 946-955
89. Diekmann, H. et al. (2009) Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish. J. Neurosci. 29, 1343-1349
90. Rodriguez-Lebron, E. and Paulson, H.L. (2006) Allele-specific RNA interference for neurological disease. Gene Ther. 13, 576-581
91. Xia, X. et al. (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol. Dis. 23, 578-586
92. Miller, V.M. et al. (2003) Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. U. S. A. 100, 7195-7200
93. Bilsen, P.H.J.V. et al. (2008) Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Human Gene Ther. 19, 710-719
94. Lombardi, M.S. et al. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 217, 312-319
95. Schwarz, D.S. et al. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2, e140
96. Zhang, Y. et al. (2009) Allele specific silencing of mutant Huntington's disease gene. J. Neurochem. 108, 82-90
97. Pfister, E.L. et al. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 19, 774-778
98. Dragatsis, I. et al. (2000) Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26, 300-306
99. Duyao, M.P. et al. (1995) Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269, 407-410
100. Boudreau, R.L. et al. (2009) Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol. Ther. 17, 1053-1063
101. McBride, J.L. et al. (2011) Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol. Ther. 19, 2152-2162
102. Grondin, R. et al. (2012) Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135, 1197-1209
103. Stiles, D.K. et al. (2012) Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp. Neurol. 233, 463-471
104. Millington-Ward, S. et al. (2011) Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol. Ther. 19, 642-649
105. Li, C. et al. (2011) Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc. Natl. Acad. Sci. U. S. A. 108, 14258-14263
106. Kubodera, T. et al. (2011) In vivo application of an RNAi strategy for the selective suppression of a mutant allele. Human Gene Ther. 22, 27-34
107. Kubodera, T. et al. (2005) New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides 15, 298-302
108. Gaj, T. et al. (2013) ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405
109. Urnov, F.D. et al. (2005) Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435, 646-651
110. Li, H. et al. (2011) In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217-221
111. Zou, J. et al. (2011) Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118, 4599-4608
112. Soldner, F. et al. (2011) Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318-331
113. Mussolino, C. et al. (2011) Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol. Med. 3, 118-128
114. Holt, N. et al. (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat. Biotechnol. 28, 839-847
115. Tebas, P. et al. (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901-910
116. Garriga-Canut, M. et al. (2012) Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc. Natl. Acad. Sci. U. S. A. 109, E3136-E3145
117. Malhotra, M. and Prakash, S. (2011) Targeted drug delivery across blood-brainbarrier using cell penetrating peptides tagged nanoparticles. Curr. Nanosci. 7, 81-93
118. O'Mahony, A.M. et al. (2013) In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery. Pharm. Res. 30, 1086-1098
119. Hwang do, W. et al. (2011) A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 32, 4968-4975
120. Li, J. et al. (2011) Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32, 4943-4950
121. Cardoso, A.L. et al. (2010) Tf-lipoplex-mediated c-Jun silencing improves neuronal survival following excitotoxic damage in vivo. J. Control. Release 142, 392-403
122. Xie, H. et al. (2011) Lactoferrin-conjugated superparamagnetic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials 32, 495-502
123. Ren, J. et al. (2012) The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33, 3324-3333
124. Ramaswamy, S. et al. (2007) Animal models of Huntington's disease. ILAR J. 48, 356-373
125. Beal, M.F. et al. (1991) Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11, 1649-1659
126. Coyle, J.T. and Schwarcz, R. (1976) Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263, 244-246
127. Beal, M.F. et al. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13, 4181-4192
128. Yang, X. and Gray, M. (2011) Mouse models for validating preclinical candidates for Huntington's disease. In Neurobiology of Huntington's Disease: Applications to Drug Discovery (Lo, D. and Hughes, R., eds), CRC Press http://www.ncbi.nlm.nih.gov/books/NBK56001/
129. Mangiarini, L. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493-506
130. Schilling, G. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant n-terminal fragment of huntingtin. Human Mol. Genet. 8, 397-407
131. Hodgson, J.G. et al. (1999) A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23, 181-192
132. Slow, E.J. et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Mol. Genet. 12, 1555-1567
133. Yu-Taeger, L. et al. (2012) A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease. J. Neurosci. 32, 15426-15438
134. Wheeler, V.C. et al. (2000) Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Human Mol. Genet. 9, 503-513
135. Menalled, L.B. et al. (2003) Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J. Comp. Neurol. 465, 11-26
136. Lin, C-H. et al. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Human Mol. Genet. 10, 137-144
137. Cattaneo, E. et al. (2005) Normal huntingtin function: an alternative approach to Huntington's disease. Nat. Rev. Neurosci. 6, 919-930
138. Kostarelos, K. and Miller, A.D. (2005) Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chem. Soc. Rev. 34, 970-994
139. Guo, J. et al. (2010) Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol. Biosyst. 6, 1143-1161
140. Krichevsky, A.M. and Kosik, K.S. (2002) RNAi functions in cultured mammalian neurons. Proc. Natl. Acad. Sci. U. S. A. 99, 11926-11929
141. Huang, B. et al. (2007) High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Human Gene Ther. 18, 303-311
142. Franich, N.R. et al. (2008) AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol. Ther. 16, 947-956
143. Burgess, A. et al. (2012) Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. J. Control. Release 163, 125-129